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Road, London
l Introduction
The diagnosis of neonatal septicaemia must be
considered in almost every sick newborn infant
[4], but definitive aetiological diagnosis and ma-
nagement, particularly treatment with antibao
terial antibiotics, poses problems. While the combi-
nation of penicillin and an aminoglycoside should
meet most bacterial eventualities [2], the pre-
sumptive diagnosis of septicaemia or other serious
microbial disease is unconfinned in most of the
babies to whom the drugs have been given, and
there is no doubt that a safe, effective alterna-
tive to the aminoglycosides is required. Because
of the emergence of lesistance in microbes pre-
viously deemed sensitive, ampicfllin is no longer
so useful äs it once was. It is important that the
first choice antibiotics should not be toxic, and
that aminoglycosides be reserved for life threaten-
mg situations and for cases in which there is a high
probabäity of infection with organisms resistant
to other antimicrobial agents.
The amidinopenicillin, mecillinam (Selexidin, LEO
LAiBORATORjEs), first described by LUND and
TYBRING [7], has an aatibacterial spectrum con-
fined to the enterte Gram-negative aerobic rods
[12] apd is bactericidal to a high percentage of
ampicilito resistnit strains of Escherichia coli {9].
Its toxicity is no greater than that of the peni-
cülins and it does not ex^rt teratogenic .effects
13]. Synergy betwe.en mesiüifiam and other -
lactam drugs has been denjcmstrated in vitro «[6,
10,13] and in vivo [53.
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In this preliminary study, we evaluate aspects of
the pharmacokinetics of mecillinam, used in com-
bination with penicülin, in the treatment of
seventy neonates in a Special Gare Baby Uni t.
Particular regard has been paid to the safety of the
agent
2 Subjects
Thirty-four male and Üiirty-six female babies, with
a inean gestational age of 34.5 ± 4.9 weeks and
mean birthweight of 2.2 ± 0.9 kg were treated by
intramuseular injection of mecillinam and peni-
ciilin. The mode pf delivery included spontaneous
vertex vaginal delivery, 24, breech delivery, 6,
forceps deUvery, 15, elective lower segment
caesarean section, 15, and emergency lower sßg-
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ment caesarean section, 6; the mode of delivery
was not recorded in four babies transferred from
other units. Fifty-four babies were preterm; thir-
teen of them being less than thirty weeks gestation
and forty-five had a birthweight of less than 2.5
kg. In all cases birth and early neonatal life were
accompanied by complications, often multiple,
known to predispose to potentially lethal infec-
tions, or to presage them [4]. They included pro-
longed rupture of membranes, 26, birth asphyxia,
12, matemal pyrexia, 9, neonatal pyrexia, 4,
meconium aspiration, 10, respiratory distress or
hyaline membrane disease, 18, pneumothorax, 5,
or fetal tachycardia, 4.
Previous to this study, all the babies would have
received either ampicillin and flucloxacillin or a
penicillin and gentamicin, depending on the gravity
of the clinical state.
2.1 Treatment regimen
The dosage regimen was mecillinam* (40 mg/kg/
day) and penicillin (60000 units/kg/day) separ-
ately administered in divided doses by intra-
muscular injection at six hourly intervals for five
days. In eleven patients treatment was not com-
pleted and for two patients further courses were
prescribed.
2.2 Laboratory investigations
The incidence of mecillinam resistant organisms
isolated from patients within the Special Gare
Baby Unit was determined before the introduction
of mecillinam and during the first six months of
use. Surface swabs and blood cultures were collec-
ted prior to treatment. Capillary samples of blood
were collected for estimation of serum urea, total
protein, albumin and alanine aminotransferase
(ALAT) before mecillinam therapy was begun,
during the third or fourth day of treatment and
two days after the course of treatment had been
completed. The results of other biochemical,
haematological and microbiological investigations
requested by paediatricians on the patients were
also analysed.
* Selexidin (kindly supplied by LEO LABORATORIES
Ltd.).
2.3 Mecillinam assay
One hundred and twentyf-one samples of blood
from 59 babies were collected for assay of mecil-
linam at timed intervals by heel prick or via an
arterial line. The assay was performed by a plate
diffusion technique using Enterobacter species
(LEO LABORATORIES HC12) äs test organism and
an assay medium consisting of 0.5% yeast extract
(Difco) in 1% agar. The indicator organism was
sensitive to mecillinam (MIC 0.5 mg/1), resistant
to penicillin and did not exhibit synergy. Assays
were set up within two hours of collection using
horse serum Standards prepared while the clinical
samples were being cöllected.
2.4 Sensitivity testing
Sensitivity of Gram-negative rods to mecillinam
was determined on Diagnostic Sensitivity Test
(DST) medium (Oxoid) using a 10 mcg disc. Initl·
ally E. coli (NCTC 10418) was used äs a control.
Later results were read from a regression line avail-
able from Leo Laboratories. The minimal inhibit-
ory concentration of mecillinam was determined
by the method of NEU [10] for all organisms ap-
pearing less sensitive than the control.
3 Results
Bacteriological investigations were undertaken in
sixty-six babies, before treatment with mecillinam
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was commenced. Two hundred and ninety-eight
specimens were examined. Pathogens or potential
pathogens were cultured from nineteen babies
(29%) in thirty-seven instances (Tab. I), and de-
tails of the bacteria isolated are shown in Tab. II.
More than one pathogen was cultured from six
babies. Gram-negative rods sensitive to mecilli-
nam were isolated from seven babies in fifteen in-
stances. None of the babies had meningitis but
blood culture was positive in nine babies (14%)
(Tab. III). Details of those in whom infection was
confirmed, or who were deemed at high risk of
serious infection supervening because pathogenic
bacteria had been isolated from parental tubes, in-
fected cord site or from multiple superficial sites
are given in Tab. III.
The sensitivity of appropriate microbes to mecil-
linam was established over a period of four months
before the introduction of mecillinam, and du ring
and after the trial, over an eight month period.
Approximately three hundred isolates of enteric,
aerobic Gram-negative rods were tested, and there
was no rise in the numbers of mecillinam resistant
organisms isolated. The sensitivity of microbes t o
the drug did not alter during treatment.
Fifty-nine babies received the füll five day course
of mecillinam with penicillin; in two of them, it
was prolonged to ten and nineteen days respect-
ively. Eleven other babies received less than the
five day course: In six, with either proven systemic
infection, 3, or deteriorating clinical state, 3, two
of whom died subsequently, mecillinam was re-
placed by gentamicin for ethical reasons; in two, it









































































* indicates a mixed culture
The figures in brackets are mecillinam or penicillin sensitive isolates.























was discontinued on discharge or on transfer for
surgery; two died of non-bacterial disease (hyaline
membrane disease; disseminated herpes) during
treatment, and all treatment was withheld from a
baby with DOWN'S syndrome.
The overall mortality in the fully and partially
treated babies was 11.4 per cent (8/70). Four
deaths occurred in the 59 babies in whom therapy
with mecillinam was completed: One baby died
of bronchopulmonaiy dysplasia, one died follow-
ing surgery and two died 4 months after being
discharged from hospital. One of these was ad-
J. Perinat. Med. 2(1981)
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mitted to another hospital and died of septi-
caemia. This baby had been treated successfully
with mecillinam for Escherichia coli septicaemia,
and succumbed, four months later, to an umelated
fiirther episode of septicaemia, diagnosed at post
mortem examination äs probably meningococcal
in origin. Four of the eleven in whom mecillinam
was discontinued also died, of disseminatedherpes,
of hyaline membrane disease, of massive pulmon-
ary haemorrhage and of intraventricular haemorr-
hage, the latter following hyaline membrane
disease and bronchopulmonary dysplasia, respec-
tively. Thus only one of the eight deaths was asso-
ciated with infection.
Biochernical tests were performed on sixty-six
babies (Tab. IV). Summating the öbservations in
the three groups tested, ihe majority of results feil
within the normal ränge for ALAT (93%) total
protein (79%) and albumin (92%); 3% had ALAT
levels above the normal ränge and 8% had abnorm -
ally low albumin levels. In 15% of .specimens
tested, total protein concentration was afaove the
normal ränge and in 6% it was below this. The
widest Variation was shown in the concentration of
serum urea, only 56% (73/131) of öbservations
lying within the normal ränge whäe 12% {1-6/131)
were abnormally high, and 32% (42/131) were
abnormally low. There was no statistically signi-
ficant difference in the values for any test on
comparison of those estimated before, during or
after treatment. The number of estimations of
serum concentration of 'sfodium and potassium
was few, but no alteratioo could be attributed
to therapy with meciUinani, There was no asso-
ciation between high ;serum bilirubin concentra-
tion and therapy.
Haeniatological investigations were performed in
forty-six babies. Haemoglobin concentration was
below 13.5 g/100 ml in fourteen and in the same
subjects the packed cefl volume was below 0.44,
The values were not affected by mecillinam
therapy nor was Üiere any adverse effect on total
or differential white ceü counts.
Oae huadred and twenty one serum samples from
59 Infants were assayed for mecillinam at rändern
time intervals after a Standard intrainuscukr dose
and the results analysed.
There was wide Variation in the serum levels
achieved at any given time after mecillinam ad-
minislratiofl,. Fig- l is a .Computer ptotted regr&s-
5100 läae based OE the data. jPeak .serum levete oc-
curred within 15 minutes of intramuscular injec-
tion, a firiding ^oufirmed by subsequent inve^ti-
gation, and sixhours after injectioji theseriimtevel
was 4—8 mg/1. The individual results for.all babies
were combined and analyised by multiple regres-
sion anailysis [1] with respect to birthweigh.t, gesta-
tiooal age, relationship to the lOth centle and neo-
Tab. IV. Biochemie^ resuits on 66 neonates treated wi
Test and ränge Pre-treatBjeivt
Number and % of
.öbservations
During trsatment
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Fig. L Computer plotted regiession line of cumulative mecillinam serum levels from 59 neonates after intramuscular
injection.
natal age when treatment commenced. These
cumulative results suggested that infants above the
lOth centile bom at less than 31 weeks gestation
had a lower peak serum level and longer half life
than those of more than 34 weeks gestation (p for
the slope <OX)5). This difference was not associ-
ated with birthweight. Infants below tiie lOth
centile for birthweight, head circumference or
length had lower serum levels if treatment was
started after the fourth neonatal day than similar
infants treated before this time (p < 0.002) or in-
fants above the lOth centile irrespective of neo-
natal age. The trough levels of mecillinam were the
same for each of these groups, The cumulative half
life for the 59 neonates studied was between 3 and
4 hours. Among infants born at less than 31 weeks
gestation the half life was slightly longer. The
reported half life in aduits is 0.8 hr. [8].
4 Discussion
PRYSE- AVIES and HURLEY [11] showed thatin-
fection was a primary cause of death in the peri-
natal period in 3.4 per cent of autopsies and a con-
tributoiy cause in up to 20 per cent. Predominant
amongst the microbes isolated was E. coli, often
resistant to ampicillin, and further analysis of their
data shows that its incidence, relative to that of
other microbes5 increased over the ten year period
of their study. There is, therefore, a good a priori
case for inclusion in the therapeutic armamen-
tarium of antibiotics active against E. coli and other
Gram-negative rods encountered in neonatal
practice. It is important that such agents should
be entirely safe, for treatment of the newborn is
often based on presumptive diagnosis [4] and, no
doubt, many are treated unnecessarily (2J.
J. Perinat. Med. 2(1981)
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The majority of systemic neonatal infections in
our unit, in the United Kingdom, are caused by
aerobic enteric Gram-negative rods (coliforms) or
Streptococcus agalactiae (LANEFIELD group B
streptococcus). Suspicion of serious infectious
disease arises in about one third of babies on our
intensive care unit, and, over the period of study
described in this paper, systemic antibiotics were
administered to seventy of 260 babies on the unit
on suspicion of serious sepsis. Previously, these
babies would have received ampicillin and flucloxa-
cillin, or a penicillin and gentamicin, depending on
the gravity of their clinical condition. All seventy
received courses of mecillinam and penicillin. For
ethical reasons, gentamicin was substituted for
mecillinam in six.
Of nine babies with positive blood cultures at the
.time of the trial, six were treated successfully with
iull courses of mecillinam and penicillin; treatment
in the other three was changed to gentamicin and
penicillin: Two of the latter died. Thus, in appro-
priately chosen cases, mecillinam seems at least äs
effective äs gentamicin in the treatment of serious
infectious disease in the newborn.
Mecillinam had no deleterious effect on liver or
renal function, äs judged by measurement of
serum ALAT, total p rotein, albumin or urea in
sixty-six of the recipients, and of serum potassium,
sodium and bilirubin in some. There was no ad-
verse effect on the haemoglobin concentration nor
on the white blood cell count. No rashes, gastro-
intestinal upsets or other ägns of drug toxicity
were noted, and resistance to the drug did not
emerge during treatment. The number of mecil-
linam resistant isolates was no higher after the trial
than before.
The wide Variation in serum levels of mecillinam
following a 10 mg/Kg intramuscular injection is
consistent with reports for other antibiotics when
used in this age group. The observation that in
neonates the half life is longer (3—4 hours) than
that reported in adults (0.8 hour) is not unex-
pected and the observation that the half life is
longer than 4 hours in neonates of less than 31
weeks gestation is compatible with the renal im-
maturity of these infants. More detailed analysis
of our fmdings would be unjustified because the
data is cumulative.
Following this study the combination of mecil-
linam and penicillin by intramuscular injection has
been used routinely in our Special Care Baby Unit
for suspect or proven serious infections for four-
teen months during which time it has proved safe
and effective.
We regafd mecillinam äs a usefül alternative to the
less safe gentamicin in cases where the latter drug
is not definitely indicated.
Summary
In an attempt to find a safe alternative to gentamicin äs
first line therapy the amidinopenicillin, mecillinam (Sele-
xidin - LEO LABORATORIES) was used to treat 70
neonates with suspected or proven infection. These pa-
tients had a mean gestational age of 34.5 ± 4.9 weeks and
a mean birthweight of less than 2.5 kg. All the babies
studied had complications of birth or early neonatal life
which are known to predispose to potentially lethal infec-
tion. The treatment regimen consisted of intramuscular
mecillinam (40 mg/Kg/day) and penicillin (60 000 unit/
Kg/day) divided into six hourly doses and administered
separately for five days. Prior to the study these neonates
would have received gentamicin and penicillin or ampicil-
lin and cloxacillin.
Pathogenic or potentially pathogenic bacteria were iso-
lated from 19 (29%) infants (Tab. I). Prior to starting
treatment 74% of isolates were sensitive to mecillinam or
penicillin. The majority of resistant organisms were
staphylococci (Tab. II). None of the babies had menin-
gitis but blood cultures from 9 were positive. Eight of the
70 neonates died; but only one of the deaths was asso-
ciated with infection and this occurred 4 months after
discharge from hospitaJ. No alteration in the sensitivity
of appropriate bacteria to mecillinam was noted during
the course of the study nor did the incidence of resistant
bacteria in the unit change after the introductionof mecil-
linam. Estimations of serum alanine aminotransferase,
total protein, albumin and urea were performed on 66
babies before, during and after mecillinam therapy. No
agnificant differences were observed (Tab. IV). Mecil-
linam therapy did not affect the haemoglobin concen-
tration, total or differential white cell count or serum
sodium or potassium levels. No adverse clinical side
effects were observed.
One hundred and twenty-one samples of serum from 59
neonates were assayed for mecillinam at varying times
after injection and the results analysed.
There was wide Variation in peak serum level (mean
17 mg/1) and persistence of the drug. Peak seium levels
occurred approximately 15 minutes aftesr intramuscular
J. Perinat. Med. 2 (1981)
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injection and six hours after injection the mean serum
level was 4-8 mg/L The serum half life was between 3
and 4 hours depending on gestational age. Multiple regres-
sion analysis of the assay results suggested that in in-
fants of <31 weeks gestation the peak serum levels
were lower and the half lifes longer than in those born
at more than 34 weeks gestation (P for the slope < 0.05).
This difference was not associated with birthweight. The
serum levei was lower in infants below the lOth centile
for birthweight, head circumference or length if treat-
ment was started after the fourth neonatal day compared
with similar babies treated before this time (P < 0.002)
or neonates above the lOth centile.
Evaluation of mecillinam in the treatment of suspected
or proven infections in neonates has shown that it is a safe
drug which is well tolerated and rapidly absorbed follow-
ing intramuscular injection. Following the study the com-
bination of mecillinam and penicülin has been used
routinely äs antibiotic treatment of first choice in our
neonatal special care unit for fourteen months. We regard
it äs a useful alternative to gentamicin in cases were the
use of an aminoglycoside is not definitively indicated.
Keywords: Bacterial infections, chemotherapy, infant, newborn, premature, low birthweight.
Zusammenfassung
Mecillinam (Selexidin) in der Therapie bei Neugeborenen
Ziel unserer Untersuchung war, eine sichere Alternative
zum Gentamycin als Primärtherapie zu finden. Wir be-
handelten darum 70 Neugeborene mit Verdacht auf oder
nachgewiesener Infektion mit Mecillinam (Selexidin —
LEO LABORATORIES). Die Kinder wurden bei einem
durchschnittlichen Gestationsalter von 34.5 ± 4.9 Wochen
geboren und hatten ein mittleres Geburtsgewicht von
weniger als 2.5 kg. Bei allen untersuchten Kindern waren
Komplikationen während der Geburt oder in den ersten
Lebenstagen aufgetreten, was als prädisponierender Fak-
tor einer potentiell letalen Infektion angesehen werden
muß. Die Medikation bestand aus einer Kombination von
Mecillinam (40 mg/kg/d) und Penicillin (60 000 Einheiten/
kg/d); die Dosen wurden i.m. in sechsstündigem Abstand
über 5 Tage jeweils separat verabreicht. Das bisherige Be-
handlungsschema bestand aus einer Kombination von
Gentamycin and Penicillin oder Ampicillin und Cloxa-
cillin.
Der Nachweis von pathogenen oder potentiell pathogenen
Bakterien gelang bei 19 Kindern, d.e. 29% (Tab. I). Von
den isolierten Keimen waren vor der Behandlung 74%
gegenüber Mecillinam oder Penicillin empfindlich. Bei den
resistenten Keimen handelte es sich überwiegend um
Staphylokokken (Tab. II). Keines der Kinder hatte kli-
nisch eine Meningitis, jedoch fanden sich bei 9 positive
Blutkulturen. 8 der 70 Neugeborenen starben; nur bei
einem ließ sich ein Zusammenhang mit einer Infektion
herstellen. Das Kind starb 4 Monate nach der Entlassung
aus dem Krankenhaus. Im Verlauf unserer Untersuchung
änderte sich die Empfindlichkeit der primär sensitiven
Keine gegenüber Mecillinam nicht. Auch die Zahl der
resisten Keime blieb nach Therapiebeginn mit Mecillinam
gleich.
Vor, während und nach der Mecillinamtherapie bestimm-
ten wir GPT-, Gesamtprotein-, Albumin- und Harnstoff-
konzentrationen. Es fanden sich keine signifikanten Un-
terschiede (Tab. IV). Auch die Hb-Konzentration sowie
die Leukozytenzahl oder auch das Differentialblutbild
wurden durch die Therapie nicht beeinflußt, ebensowenig
die Na*- und KMVerte im Serum. Das klinische Bild ent-
sprach diesen Befunden.
Bei 59 Neugeborenen wurden in definierten Zeitabstän-
den nach der Injektion insgesamt 121 Blutproben ent-
nommen und auf Mecillnam untersucht.
Es fand sich eine große Streubreite hinsichtlich der Peak-
Konzentrationen (x = 17 mg/1) und Halbwertszeiten.
Die maximale Konzentration im Serum war etwa 15 min
nach der intramuskulären Injektion erreicht, und 6 h nach
der Injektion betrug die mittlere Serumkonzentration
4-8 mg/L Die Halbwertszeit lag zwischen 3 und 4 h in
Abhängigkeit vom Schwangerschaftsalter zum Zeitpunkt
der Geburt. Die multiple Regressionsanalyse ergab, daß
bei Kindern unterhalb der 31. Woche die Peakkonzentra-
tionen niedriger und die Halbwertszeiten länger waren als
bei Kindern, die jenseits der 34. Schwangerschaftswoche
geboren waren. Diese Unterschiede fanden sich unab-
hängig vom Geburtsgewicht. Auch lag der Serumspiegel
niedriger bei Kindern unterhalb der lOer-Perzentile —
bezogen auf Geburtsgewicht, Kopfumfang und Länge -,
wenn die Behandlung nach dem 4. Lebenstage begonnen
wurde, gegenüber Kindern gleicher Reife, die schon früher
behandelt wurden (p < 0.002) oder Neugeborenen ober-
halb der 10er Perzentile.
Die Untersuchung zum Einsatz von Mecillinam bei Ver-
dacht auf oder nachgewiesener Infektion bei Neugebore-
nen hat ergeben, daß es sich um ein sicheres, gut tole-
riertes und nach i.m.-Injektion schnell absorbiertes Phar-
makon handelt. Nach dieser Studie wurde die Kombina-
tion von Mecillinam und Penicillin als antibiotische
Therapie erster Wahl in unserer Neugeborenenstation
über 14 Monate eingesetzt. Wir glauben, daß Mecillinam
eine gute Alternative zum Gentamycin darstellt, und zwar
in allen Fällen, wo Amino glycoside nicht eindeutig in-
diziert sind.
Schlüsselwörter: Bakterielle Infektionen, Chemotherapie, Frühgeborenes, geringes Geburtsgewicht, Kind, Neugeborenes.
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Resume
Traitement des nouveaux-nes par le mecillinam (Selexi-
dine)
D ans le but de trouver une alternative süre de la genta-
micine en tant que traitement de premiere intention, nous
avons utilise ramidinopenicilline le mecillinam (Selexidin
- LABORATOIRES LEO) dans le traitement de 70 in-
fections neonatologiques prouvees ou suspectees. L'äge
gestationnel moyen etait de 34,5 ± 4,9 semaines et le
poids de naissance moyen n'exedait pas 2500 g. Tous ces
nouveaux-nes montraient des complication natales ou
neonataies precoces connues pour predisposer a des infec-
tion potentiellement letales. La dose intramusculaire
etait de 40 mg/kg/jour de mecillinam et de 60 000 Unites/
kg/jour de penicilline divises en des doses appliquees
toutes les 6 heures pendant 5 jours. Avant cette etude ces
nouveaux-nes auraient re$u de la gentamicine et de la
penicilline ou bien de l'ampicilline et de la cloxacilline.
Des germes pathogenes ou potentiellement pathogenes
ont ete isoles chez 19 enfants (29%) - (tableau l),
Avant d'instaurer le traitement 74% des germes isoles
etaient sensibles ä la mecilinam ou a la penicilline. Ls
majorite des organismes resistants etaient des staphylo-
cöccoques (tableau 2). Aucun nouveau-^ne ne prosentait
une meningite mais les cultures de sang de 9 d'entre eux
etaient positives. Huit des 70 nouveaux-nes moururent;
mais seul un deces etait lie a une infection et cela arriva 4
mois apres la sortie de Fhopital. La sensibilitedesbacteries
appropriees pour la mecillinam ne s'altera pas au cours de
Petude; il n'y a pas eu d'incidence sur les germes resistants
dans Punite apres Fintroduction de la mecillinam. Nous
avons doses chez 66 nouveaux-nes avant, pendant et apres
le traitement ä le mecillinam Falamnine-aminotransferase
serique, les proteines totaux, falbumine et Furee. Nous
n'avons point note de differences significatives. (tableau
4). Le traitement par la mecillinam n'affecte pas la con-
centration en hemoglobine, la nümeration globale ou la
formule des globules blancs ni. ̂ es valeurs seriques de K et
de Na. Nous n'avons pas note des effets secondaires cli-
niques.
Cent vingt et un echantillons de serum de 59 nouveaux-
nes ont ete doses quant a la mecillinam apres des temps
variables suivant Tadministration et les resultats ont ete
analyses.
Une large variabilite du pic serique (moyenne 17 mg/1) et
de la persistance de la drogue ont ete observees. Les pics
etaient atteints environ 15 minutes apres rinjectipn in-
tramusculaire et 6 heures apres l'injection les valeurs
moyennes seriques attaignaient 4 a 8 mg/1. La demi-vie
serique se situait entre 3 et 4 heures en fonction de l'age
gravidique. Des analyses de regression multiples ont
montre que chez les enfants de moins de 31 semaines le
pic serique etait plus bas et les demi vies etaient plus
longues par rapport ä ceux des nes apres la 34eme semaine
(p inf. a 0.05). Cette difference n'est pas liee au poids
de naissance. La valeur serique etait plus basse chez les
enfants au dessous du lOerne percentile de poids de nais-
sance, de perimetre cranien ou de longueur si le traite-
ment etait debute apres le 4eme jour apres la naissance,
en comparaison avec des nouveaux-nes similaires traites
avant ce delai (p inf a 0,002) ou les nouveaux-nes au delä
du lOeme percentile.
Le mecillinam dans le traitement d'infections prouvees ou
suspectees des nöuveaux-nes est une drogue süre et bien
toleree ainsi que rapidement absorbee apres administra-
tion intramusculake. A la suite de cette etude nous avons
utilise la combinaison de mecillinam et de penicilline de
fa$on systematique en tant que traitement de premiere
intention dans notre unite perinatologique duramt 14
mois. Nous le considerons comme une alternative utile de
la gentamycine dans les cas ou l'utüisation d'un amino-
glycoside n'est pas definitivement indiquee.
Mots-cles: Chimiotherapie, enfant, faible poids de naissance, infections bacteriennes, nouveau-ne, premäture.
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